IDEAYA Biosciences, Inc.

Equities

IDYA

US45166A1025

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 25/05/2024 am IST			5-day change	1st Jan Change
37.71 ^USD	-1.92%		-6.89%	+5.99%

16/05	Ideaya Biosciences Insider Sold Shares Worth $7,397,291, According to a Recent SEC Filing	MT
08/05	Oppenheimer Adjusts IDEAYA Biosciences Price Target to $53 From $50, Maintains Outperform Rating	MT

IDEAYA Biosciences, Inc. Appoints Susan L. Kelley to its Board of Directors

February 17, 2021 at 04:30 pm IST

IDEAYA Biosciences, Inc. announced the appointment of Susan Kelley, M.D., to its board of directors. Dr. Kelley brings over 25 years of experience in oncology drug research and development to IDEAYA. Most recently she served as Chief Medical Officer of the Multiple Myeloma Research Consortium (MMRC) where she led the strategic design and management of clinical trials in North America.

Latest news about IDEAYA Biosciences, Inc.

Ideaya Biosciences Insider Sold Shares Worth $7,397,291, According to a Recent SEC Filing	17/05	MT
Oppenheimer Adjusts IDEAYA Biosciences Price Target to $53 From $50, Maintains Outperform Rating	08/05	MT
IDEAYA Biosciences Shares Fall After Q1 Loss	07/05	MT
IDEAYA Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05	CI
IDEAYA Biosciences Selects Move-Forward Expansion Dose for Mid-Stage Trial of IDE397 Monotherapy	22/04	MT
IDEAYA Biosciences, Inc. Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer	22/04	CI
Citigroup Raises IDEAYA Biosciences' Price Target to $60 From $40, Maintains Buy Rating	21/03	MT
IDEAYA Biosciences, Merck Sign Deal to Evaluate IDE161 in Combination with Keytruda to Treat Endometrial Cancer Patients	12/03	MT
IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer	12/03	CI
BTIG Starts Coverage on IDEAYA Biosciences With Buy Rating, $55 Price Target	08/03	MT
Transcript : IDEAYA Biosciences, Inc. Presents at Citi 2024 Virtual Oncology Leadership Summit, Feb-21-2024 08:00 AM	21/02
RBC Raises Price Target on IDEAYA Biosciences to $53 From $43 on 'Clarity & Confidence on Daro's Potential,' Keeps Outperform Rating, Speculative Risk	21/02	MT
Wedbush Raises IDEAYA Biosciences' PT to $52 From $46, Updates Model to Include Recent Financings; Keeps Outperform Rating	20/02	MT
IDEAYA Biosciences Q4 Loss Widens, Revenue Declines	20/02	MT
Earnings Flash (IDYA) IDEAYA BIOSCIENCES Posts Q4 Revenue $3.9M	20/02	MT
IDEAYA Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/02	CI
IDEAYA Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	20/02	CI
Ideaya Biosciences Insider Sold Shares Worth $4,495,550, According to a Recent SEC Filing	13/02	MT
Goldman Sachs Adjusts Price Target on IDEAYA Biosciences to $53 From $36, Maintains Buy Rating	25/01	MT
Wedbush Raises Price Target on IDEAYA Biosciences to $46 From $43, Maintains Outperform Rating	16/01	MT
RBC Adjusts IDEAYA Biosciences' Price Target to $43 From $36, Keeps Outperform Rating	10/01	MT
Transcript : IDEAYA Biosciences, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 08:15 AM	09/01
Ideaya Biosciences Insider Sold Shares Worth $350,371, According to a Recent SEC Filing	20/12	MT
Ideaya Biosciences Insider Sold Shares Worth $2,627,618, According to a Recent SEC Filing	20/12	MT
IDEAYA Biosciences Collaborates With Gilead Sciences to Evaluate Combination of Trodelvy, IDE397 for Bladder Cancer	04/12	MT

Chart IDEAYA Biosciences, Inc.

Duration

Period

More charts

Company Profile

IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates are darovasertib (IDE196), IDE397, IDE161 and GSK101 (Pol Theta Helicase). IDE196, a small molecule protein kinase C (PKC), inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397, is its small molecule methionine adenosyltransferase 2a (MAT2A), inhibitor. IDE161, is its small molecule poly (ADP-ribose) glycohydrolase (PARG), inhibitor. IDE196 is its clinical-stage PKC inhibitor that the Company is evaluating as a synthetic lethal combination therapy. IDE397, a MAT2A inhibitor for patients with solid tumors having MTAP deletions. IDE161 is its clinical-stage, potent and selective small molecule inhibitor of PARG for patients having tumors with defined biomarkers based on genetic mutations and/or molecular signatures.

Sector

Biotechnology & Medical Research

Calendar

01/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for IDEAYA Biosciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

37.71 USD

Average target price

52.82 USD

Spread / Average Target

+40.06%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IDEAYA BIOSCIENCES, INC.	+5.99%	2.91B
MODERNA, INC.	+67.53%	62.86B
IQVIA HOLDINGS INC.	-0.77%	41.38B
LONZA GROUP AG	+45.66%	40.38B
CELLTRION, INC.	-10.72%	27.64B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.46B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.9B
BIO-TECHNE CORPORATION	+4.70%	12.67B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.27B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B

Other Biotechnology & Medical Research